334 M. Jenny et al.: [28] Lewis JR. Amaryllidaceae and Sceletium alkaloids. Nat Prod Rep. 1994; 11: 329–332. doi:10.1039/NP9941100329 [29] Tram NT, Mitova M, Bankova V, Handjieva N, Popov SS. GC-MS of Crinum latifolium L. alkaloids. Z Naturforsch C. 2002; 57: 239–242. PMid:12064720 [30] Griffin C, Sharda N, Sood D, Nair J, McNulty J, Pandey S. Selective cytotoxicity of pancratistatin-related natural Amaryllidaceae alkaloids: evaluation of the activity of two new compounds. Cancer Cell Int. 2007; 7: 10. doi:10.1186/1475-2867-7-10 [31] McNulty J, Nair JJ, Codina C, Bastida J, Pandey S, Gerasimoff J, Griffin C. Selective apoptosis-inducing activity of crinum-type Amaryllidaceae alkaloids. Phytochemistry. 2007; 68: 1068–1074. doi:10.1016/j.phytochem.2007.01.006 [32] Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Wachter H. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J. 1989; 262; 861–866. PMid:2511835 [33] Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003; 9: 1269–1274. doi:10.1038/nm934 [34] Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008; 222: 206–221. doi:10.1111/j.1600-065X.2008.00610.x [35] Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002; 101: 151–155. doi:10.1002/ijc.10645 [36] Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005; 11: 312–319. doi:10.1038/nm1196 [37] Gaspari P, Banerjee T, Malachowski WP, Muller AJ, Prendergast GC, DuHadaway J, Bennett S, Donovan AM. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2006; 49: 684–692. doi:10.1021/jm0508888 [38] Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene. 2008; 27: 2851–2857. doi:10.1038/sj.onc.1210939 Sci Pharm. 2011; 79: 323–335